ArticleMolecular cancer therapeutics2016

A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

David A Alagpulinsa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.